Companies /Healthcare

Neogenomics Inc

NASDAQ: NEO Diagnostics & Research
$15.59
▼ $0.43 (−2.68%) today
Markets open · 2:21pm ET

NEO at a Glance

Valuation
Market cap
$2.1B
Profitability
Revenue (TTM)
$787.8M
Profit margin
-4.1%
EPS (TTM)
$-0.24
Price
52-week range
$7 – $20
Street target
$23.40

Headquartered in Fort Myers, FL Fiscal year ends December NASDAQ: NEO neogenomics.com

About Neogenomics

NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company specializing in cancer genetics testing and information services.

Its oncology-focused testing menu spans the cancer continuum and includes:
- next-generation sequencing (NGS)
- molecular residual disease (MRD) testing such as RaDaR ST, which now holds three Medicare-covered indications
- other diagnostic and predictive tests

Its customers include oncologists, pathologists, hospital systems, academic medical centers and pharmaceutical firms. Revenue comes mainly from clinical services, which generated about 93% of Q3 2026 revenue. The remainder comes from non-clinical activity, such as pharma services.

The company operates a network of CAP-accredited and CLIA-certified laboratories across the US and a CAP-accredited sample-processing lab in Cambridge, England. It is investing in NovaSeq X sequencing capacity, IT systems and revenue cycle management. It is also expanding commercial payer in-network agreements.

The company is funded partly through convertible senior notes. A planned CEO transition from Tony Zook to Warren Stone takes effect January 4, 2027. Updated

NEO Coverage

Frequently Asked Questions

What does Neogenomics do?

NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company specializing in cancer genetics testing and information services.

What is the NEO stock price target?

The Wall Street consensus 12-month price target for NEO is $23.40.